Literature DB >> 11743357

Prognostic value of a T helper 1 urinary cytokine response after intravesical bacillus Calmette-Guerin treatment for superficial bladder cancer.

Fabien Saint1, Jean J Patard, Pascale Maille, Pascale Soyeux, André Hoznek, Laurent Salomon, Claude C Abbou, Dominique K Chopin.   

Abstract

PURPOSE: Interleukin (IL)-2 and interferon-gamma are released during T helper 1 lymphocyte responses, while IL-10 is released during T helper 2 responses. We evaluated the prognostic value of urinary IL-2, interferon-gamma and IL-10 levels in patients with superficial bladder cancer treated with bacillus Calmette-Guerin (BCG) instillation.
METHODS: Urinary IL-2, interferon-gamma and IL-10 were measured by enzyme-linked immunosorbent assay in 37 patients receiving BCG for stages Ta/T1 superficial bladder cancer, and carcinoma in situ. Measurements were made after instillations 5 and 6 during a course of 6 weekly instillations of 150 mg. BCG, Pasteur strain. Correlations of cytokine levels with the clinical outcome were evaluated using the log rank test.
RESULTS: Median followup was 29 months. Patients with urinary IL-2 less than 27 pg./micromol. creatinine were significantly more likely to have recurrences than those with higher values (log rank test p = 0.0009). Urinary IL-10 and interferon-gamma levels had no apparent impact on the risk of recurrence or progression.
CONCLUSION: Urinary IL-2 levels may serve to identify patients at risk for bladder cancer recurrence after a single course of BCG and, thus, to tailor individual treatment.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11743357

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  28 in total

Review 1.  Management of carcinoma in situ of the bladder: best practice and recent developments.

Authors:  Dominic H Tang; Sam S Chang
Journal:  Ther Adv Urol       Date:  2015-12

2.  Mycobacterium bovis bacillus Calmette-Guérin (BCG) induces human CC- and CXC-chemokines in vitro and in vivo.

Authors:  Y Luo; X Chen; M A O'Donnell
Journal:  Clin Exp Immunol       Date:  2007-02       Impact factor: 4.330

3.  Evaluation of the Efficacy of the H. pylori Protein HP-NAP as a Therapeutic Tool for Treatment of Bladder Cancer in an Orthotopic Murine Model.

Authors:  Gaia Codolo; Fabio Munari; Matteo Fassan; Marina de Bernard
Journal:  J Vis Exp       Date:  2015-05-29       Impact factor: 1.355

Review 4.  Immune therapies in non-muscle invasive bladder cancer.

Authors:  Philip L Ho; Stephen B Williams; Ashish M Kamat
Journal:  Curr Treat Options Oncol       Date:  2015-02

Review 5.  Biomarkers for precision medicine in bladder cancer.

Authors:  Takahiro Kojima; Koji Kawai; Jun Miyazaki; Hiroyuki Nishiyama
Journal:  Int J Clin Oncol       Date:  2016-11-29       Impact factor: 3.402

6.  Predicting response to bacillus Calmette-Guérin (BCG) in patients with carcinoma in situ of the bladder.

Authors:  Rafael Nunez-Nateras; Erik P Castle; Cheryl A Protheroe; Melissa L Stanton; Tolgay I Ocal; Erin N Ferrigni; Sergei I Ochkur; Elizabeth A Jacobsen; Yue-Xian Hou; Paul E Andrews; Thomas V Colby; Nancy A Lee; James J Lee
Journal:  Urol Oncol       Date:  2013-09-18       Impact factor: 3.498

7.  Interleukin-10 inhibits Mycobacterium bovis bacillus Calmette-Guérin (BCG)-induced macrophage cytotoxicity against bladder cancer cells.

Authors:  Y Luo; R Han; D P Evanoff; X Chen
Journal:  Clin Exp Immunol       Date:  2010-02-10       Impact factor: 4.330

8.  Role of Th1-stimulating cytokines in bacillus Calmette-Guérin (BCG)-induced macrophage cytotoxicity against mouse bladder cancer MBT-2 cells.

Authors:  Y Luo; H Yamada; D P Evanoff; X Chen
Journal:  Clin Exp Immunol       Date:  2006-10       Impact factor: 4.330

Review 9.  Mycobacterium bovis bacillus Calmette-Guérin-induced macrophage cytotoxicity against bladder cancer cells.

Authors:  Yi Luo; Matthew J Knudson
Journal:  Clin Dev Immunol       Date:  2010-09-01

10.  Recombinant Mycobacterium bovis bacillus Calmette-Guérin (BCG) expressing mouse IL-18 augments Th1 immunity and macrophage cytotoxicity.

Authors:  Y Luo; H Yamada; X Chen; A A Ryan; D P Evanoff; J A Triccas; M A O'Donnell
Journal:  Clin Exp Immunol       Date:  2004-07       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.